Immatics N.V. Reports Promising Clinical Data for TCR Bispecific Molecules and Advances Four Cancer Therapy Candidates
Immatics targets five cancer types with TCR-T therapies; recent data shows promising results for TCER® IMA402 and ACTengine® IMA203.Quiver AI SummaryImmatics N.V. announced a strategic expansion of its...
Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors
/PRNewswire / Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of...
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
Collaboration combines leading technologies to develop breakthrough, mRNA-enabled in vivo expressed TCER® molecules
Why Immatics Stock Is Soaring Today
Investors liked what they heard in Immatics' interim results for experimental immunotherapy IMA203.